Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.
Phase of Trial: Phase IV
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Lobeglitazone (Primary) ; Sitagliptin (Primary) ; Glimepiride/metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Triple3
- 09 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.
- 31 Aug 2018 Biomarkers information updated
- 05 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.